Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7764957 | 0.81 | CRBN (0.48) | CYP3A4ALDH1A1DAONPC1RAB9A | |
| SCHEMBL18214339 | 0.78 | CYP3A4 (0.78) | CYP3A4DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL30330184 | 0.74 | CYP19A1 (0.50) | CYP3A4POLB | |
| SCHEMBL8805151 | 0.74 | DRD2 (0.53) | DRD2DRD4DRD3TAAR1SIGMAR1 | |
| SCHEMBL19294797 | 0.72 | CYP3A4 (0.34) | CYP3A4 | |
| SCHEMBL12019823 | 0.72 | MAOB (0.57) | CYP3A4ALDH1A1TDP1NPC1RAB9A | |
| SCHEMBL16982213 | 0.70 | MEN1 (0.39) | ALDH1A1NPC1RAB9A | |
| SCHEMBL8396285 | 0.70 | KAT2A (0.39) | POLB | |
| SCHEMBL10295293 | 0.70 | MAPT (0.50) | ALDH1A1TDP1NPC1RAB9A | |
| SCHEMBL8027251 | 0.69 | DRD2 (0.39) | CYP3A4DRD2DRD4DRD3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818780-B2 | APPLICATION IN MEDICINE FOR TREATMENT OF DISORDERS OF IMMUNOLOGICAL SYSTEM | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2004-11-16 | — | — | US | disclosed |
| EP-1284263-B1 | DERIVATIVES OF P- HYDROXY PHENYL PROPIONIC ACID AS ANTIPROLIFERATIVE AGENTS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2003-12-10 | — | — | EP | disclosed |
| US-20030199575-A1 | P-hydroxyphenyl propionic acid derivatives as antiproliferative agents | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2003-10-23 | — | — | US | disclosed |
| EP-1284263-A1 | DERIVATIVES OF P- HYDROXY PHENYL PROPIONIC ACID AS ANTIPROLIFERATIVE AGENTS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199575-A1 | P-hydroxyphenyl propionic acid derivatives as antiproliferative agents | P4HA1, PAH, VHL | CYP3A4 2191/4885DRD2 4248/4885DRD4 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.